J Korean Soc Hypertens.  2010 Dec;16(4):44-53.

Telmisartan Versus Carvedilol in Hypertensive Patients with Metabolic Syndrome: Effects on Blood Pressure, Arterial Stiffness, Blood Glucose, and Lipid Metabolism

Affiliations
  • 1Cardiovascular Center, Dongguk University Ilsan Hospital, Goyang, Korea. ykkim@dumc.or.kr
  • 2Department of Internal Medicine, Dongguk University Gyeongju Hospital, Gyeongju, Korea.
  • 3Department of Laboratory Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.

Abstract

BACKGROUND
We compared the effects of telmisartan and carvedilol on blood pressure (BP), aortic stiffness, glucose, and lipid metabolism in hypertensive patients with metabolic syndrome (MS).
METHODS
A total of 26 untreated hypertensive patients with MS was randomly assigned into either telmisartan (N=13) or carvedilol (N=13) group and treated for a 24-week period. Systolic and diastolic BPs were measured every 4 weeks. Fasting plasma glucose (FG), total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL), LDL-cholesterol (LDL), adiponectin, brachial-ankle pulse wave velocity (baPWV), and heart-femoral PWV (hfPWV) were measured at baseline and at weeks 12 and 24.
RESULTS
Systolic and diastolic BPs, baPWV, hfPWV were significantly decreased in both groups and there were no significant differences in the changes of BP, baPWV, and hfPWV between the two groups during the treatment period. In telmisartan group, there were no significant changes in levels of FG, TC, TG, HDL, LDL, and adiponectin at week 24. In carvedilol group, there were no significant changes in levels of FG, TC, and LDL at week 24. However, TG level was significantly increased (baseline, 162.9+/-64.6 mg/dL; week 24, 198.0+/-69.8 mg/dL; p=0.046), and levels of HDL (baseline, 48.7+/-8.8 mg/dL; week 24, 42.9+/-7.2 mg/dL; p=0.044) and adiponectin (baseline, 7.0+/-4.1 microg/mL; week 24 5.8+/-3.2 microg/mL; p=0.003) were significantly decreased.
CONCLUSION
Telmisartan and carvedilol are comparable in reducing BP and aortic stiffness. However, compared with telmisartan, carvedilol may adversely affect adiponectin level and lipid metabolism without adverse impact on FG in hypertensive patients with MS.

Keyword

Telmisartan; Carvedilol; Hypertension; Metabolic Syndrome
Full Text Links
  • JKSH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr